Oncology Today with Dr Neil Love

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:
Introduction (00:00)
Overview of Ovarian Cancer (OC) (2:12)
Role of PARP Inhibitors in Advanced OC (4:56)
Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
Role of Relacorilant in Advanced OC (57:08)
Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:
Introduction (0:00)
Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)

CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics:
Introduction (00:00)
Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)
EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)
Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)
Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)
Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Introduction (00:00)
Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:
Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications